Shire SHP-GCB-402: An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment with Velaglucerase alfa on Bone-related Pathology in Treatment-naive Patients with Type 1 Gaucher Disease

Project: Research project

Project Details

StatusFinished
Effective start/end date6/30/17 → 6/30/20

Funding

  • Shire Human Genetic Therapies, Inc.